Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ACTU 
Actuate Therapeutics, Inc. Common stock (ACTU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ACTU (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $26.75
1 Year Target Price $26.75
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.91% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 181.30M USD | Price to earnings Ratio - | 1Y Target Price 26.75 |
Price to earnings Ratio - | 1Y Target Price 26.75 | ||
Volume (30-day avg) 3 | Beta - | 52 Weeks Range 5.47 - 11.99 | Updated Date 10/17/2025 |
52 Weeks Range 5.47 - 11.99 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.11 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -348.95% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 162046155 | Price to Sales(TTM) - |
Enterprise Value 162046155 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 23243328 | Shares Floating 11381432 |
Shares Outstanding 23243328 | Shares Floating 11381432 | ||
Percent Insiders 16.14 | Percent Institutions 48.96 |
Upturn AI SWOT
Actuate Therapeutics, Inc. Common stock
Company Overview
History and Background
Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on developing new medicines for cancers that have become resistant to standard therapies. They are pioneering the development of novel therapies with the potential to transform the treatment of advanced cancers.
Core Business Areas
- Drug Development: Actuate focuses on the research and development of new drug candidates, specifically targeting the treatment of advanced cancers resistant to standard therapies.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates in patients with advanced cancers.
Leadership and Structure
Specific details about the leadership team and organizational structure are not readily available publicly. Check the company's investor relations website.
Top Products and Market Share
Key Offerings
- G-305: Actuate's lead drug candidate, G-305, is designed to inhibit PI3K signaling and has shown encouraging early clinical data. It is currently in clinical development for various advanced cancers. Market share data is not yet available due to its developmental stage. Competitors include other companies developing PI3K inhibitors.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and dynamic, with significant investments in research and development of new cancer therapies. Demand for innovative cancer treatments continues to grow.
Positioning
Actuate Therapeutics is positioned as an innovative biotech company focused on developing therapies for resistant cancers. Their competitive advantage lies in their unique approach to targeting PI3K signaling.
Total Addressable Market (TAM)
The total addressable market for cancer therapeutics is substantial, reaching hundreds of billions of dollars globally. Actuate is targeting a specific niche within this market u2013 cancers resistant to current treatments - positioning them to capture a portion of the market with successful drug development.
Upturn SWOT Analysis
Strengths
- Novel drug candidate with a unique mechanism of action
- Strong preclinical and early clinical data
- Experienced management team
Weaknesses
- Early-stage company with limited resources
- Dependence on a single drug candidate
- High risk of clinical trial failure
Opportunities
- Potential for breakthrough therapy designation
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Unfavorable clinical trial results
Competitors and Market Share
Key Competitors
- BAYRY
- GILD
- NOVN
Competitive Landscape
Actuate faces competition from established pharmaceutical companies with broader pipelines and more resources. Their advantage lies in their unique approach to drug development.
Growth Trajectory and Initiatives
Historical Growth: N/A
Future Projections: Future growth depends on successful clinical trial outcomes and potential commercialization of G-305. Analyst estimates are not widely available due to the company's stage.
Recent Initiatives: Focusing on advancing their lead drug candidate, G-305, through clinical trials.
Summary
Actuate Therapeutics is an early-stage biopharmaceutical company with a promising lead drug candidate targeting resistant cancers. Their success hinges on the outcomes of clinical trials and their ability to secure funding and partnerships. While possessing innovative science and an experienced team, they face the inherent risks associated with drug development and competition from larger pharmaceutical companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Financial News Outlets
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Actuate Therapeutics, Inc. Common stock
Exchange NASDAQ | Headquaters Fort Worth, TX, United States | ||
IPO Launch date 2024-08-13 | CEO, President & Director Mr. Daniel M. Schmitt | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | Website https://actuatetherapeutics.com |
Full time employees 10 | Website https://actuatetherapeutics.com | ||
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.